Phospho-PDE4B/PDE4C/PDE4D (S133/119/190) Antibody

What cellular functions do PDE4B, PDE4C, and PDE4D regulate?

PDE4 enzymes (including subtypes B, C, and D) play critical roles in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) and are involved in various signaling pathways that control immune response, cell proliferation, and neurotransmission. These enzymes hydrolyze the second messenger cAMP, which is a key regulator of many important physiological processes .

Specifically, PDE4 enzymes are involved in:

• Signal transduction pathways

• Inflammatory responses in immune cells

• Central nervous system functions

• Cell proliferation mechanisms

• Neurotransmission pathways

The phosphorylation of PDE4 isoforms at specific sites (S133/119/190) can modulate their enzymatic activity and localization, which impacts downstream cellular functions in various tissues and cell types .

What are the recommended applications for Phospho-PDE4B/PDE4C/PDE4D (S133/119/190) Antibody?

This antibody has been validated for several key research applications:

For optimal results in Western blot applications, researchers should first determine optimal antibody concentrations using positive control samples. This antibody allows for the detection and quantification of phosphorylated PDE4B, PDE4C, and PDE4D in cell lysates, providing insights into the signaling events associated with cAMP regulation .

What species reactivity has been confirmed for this antibody?

The Phospho-PDE4B/PDE4C/PDE4D (S133/119/190) Antibody has been confirmed to react with samples from the following species:

• Human

• Mouse

• Rat

This cross-species reactivity has been validated in multiple applications (WB, IHC, ELISA) . This broad species reactivity makes the antibody versatile for comparative studies across different experimental models.

What is the recommended protocol for detecting phosphorylated PDE4B/C/D in primary T cells?

For detecting phosphorylated PDE4B/C/D in primary T cells, researchers should follow these methodological steps:

• Cell Isolation and Stimulation:

  • Isolate CD4+ or CD8+ T cells from peripheral blood using appropriate antibody-coated paramagnetic beads

  • For activation studies, stimulate with anti-CD3/CD28 antibodies (which has been shown to increase the expression of PDE4 subtypes)

• Lysate Preparation:

  • Harvest cells at appropriate time points (PDE4A and PDE4D show sustained upregulation over 5 days, while PDE4B shows transient upregulation with highest levels after 24h)

  • Lyse cells in buffer containing phosphatase inhibitors to preserve phosphorylation status

• Western Blot Analysis:

  • Use 1:500-1:2000 dilution of phospho-specific antibody

  • Include appropriate controls (total PDE4 antibodies, loading controls like β-actin)

  • For T cell studies, note that PDE4 expression patterns differ between CD4+ and CD8+ subpopulations

This approach enables accurate detection of phosphorylation-dependent changes in PDE4 activity within lymphocyte populations during immune responses or in disease models .

How can researchers effectively validate the specificity of Phospho-PDE4B/PDE4C/PDE4D antibody signals?

Validating antibody specificity is crucial for reliable research outcomes. For Phospho-PDE4B/PDE4C/PDE4D (S133/119/190) Antibody, implement these validation strategies:

• Phosphatase Treatment Controls:

  • Treat one sample set with lambda phosphatase before antibody application

  • Compare with untreated samples to confirm phospho-specificity

• Stimulation Experiments:

  • Use forskolin treatment to increase cAMP levels, which enhances PDE4D phosphorylation as detected by phospho-PKA substrate antibody

  • Compare baseline vs. stimulated samples

• Phospho-Defective Mutation Controls:

  • If possible, use cells expressing phospho-defective mutations (e.g., S190A mutation makes PDE4D resistant to RRXS/T phosphorylation)

• Subtype Specificity Assessment:

  • Use PDE4 subtype knockout models (e.g., PDE4A, PDE4B, or PDE4D deficient cells) to confirm signal absence for specific subtypes

  • Sibling-matched wild-type cells should be used as positive controls

These validation approaches ensure that signals detected by the antibody truly represent phosphorylated PDE4 isoforms rather than non-specific binding or artifacts .

How does the phosphorylation status of PDE4B/C/D correlate with T cell activation and cytokine production?

The phosphorylation status of PDE4 subtypes plays a critical role in T cell function through complex temporal regulation:

• Differential Expression Patterns:

  • Anti-CD3/CD28 stimulation of human primary CD4+ T cells increases expression of PDE4A, PDE4B, and PDE4D in a time-dependent manner

  • PDE4A and PDE4D mRNAs and enzyme activities are up-regulated within 5 days

  • PDE4B shows transient up-regulation with highest levels after 24 hours

• Subtype-Specific Roles in Cytokine Production:

  • Knockdown experiments using subtype-specific siRNAs show:

    • PDE4B and PDE4D inhibition reduces IL-2 release at 24h (maximal IL-2 concentration timepoint)

    • PDE4D knockdown predominantly affects IFN-γ and IL-5 production at later timepoints (72h)

    • Combined PDE4 subtype inhibition provides most effective cytokine suppression

• Impact on T Cell Proliferation:

  • PDE4D targeting is as effective as pan-PDE4 inhibition in suppressing T cell proliferation

  • PDE4A or PDE4B knockdown has minimal effect on proliferation

This temporal and functional specificity suggests that phosphorylation-dependent regulation of different PDE4 subtypes creates a sophisticated control system for T cell activation and cytokine production, with potential implications for immunomodulatory therapeutic approaches .

What are the molecular mechanisms by which PDE4D phosphorylation affects mTORC1 signaling pathways?

Recent research has revealed a novel relationship between PDE4D phosphorylation and mTORC1 signaling:

• Phosphorylation Sites and PKA Regulation:

  • PDE4D contains two predicted PKA substrate motifs: RRXS/T on Ser190 and KKXS/T on Thr595

  • Forskolin treatment increases PDE4D phosphorylation as determined by phospho-PKA substrate antibody

  • A phospho-defective Ser190 mutation (S190A) renders PDE4D resistant to RRXS/T phosphorylation in response to forskolin

• Impact on mTORC1 Pathway:

  • PDE4D promotes pancreatic cancer tumor growth by increasing mTORC1 signaling

  • PDE4D overexpression decreases Raptor Ser791 phosphorylation, even when FLAG-tagged PDE4D carries mutations (S190A and T595A)

• Functional Consequences:

  • The relationship between PDE4D and mTORC1 provides a mechanistic link between cAMP signaling and cellular growth control

  • This pathway offers a potential therapeutic target for cancer treatment strategies

Understanding these molecular interactions provides insight into how phosphorylation-dependent regulation of PDE4D contributes to broader signaling networks beyond direct cAMP hydrolysis .

How does PDE4 subtype-specific phosphorylation contribute to β-adrenergic receptor signaling and desensitization?

PDE4 subtype-specific phosphorylation plays a crucial role in the regulation of β2-adrenergic receptor (β2AR) signaling:

• Subtype Specificity in cAMP Accumulation:

  • Studies using mouse embryonic fibroblasts (MEFs) deficient in single PDE4 genes reveal:

    • PDE4D, but not PDE4A or PDE4B, is the major determinant in controlling cAMP accumulation after β2AR stimulation

    • PKA-mediated phosphorylation and activation of PDE4D critically regulates this process

• Impact on Receptor Desensitization:

  • PDE4D specifically defines the time course of β2AR uncoupling and desensitization

  • PDE4D ablation disrupts desensitization and β2AR coupling to Gαi

• Downstream Signaling Effects:

  • The altered cAMP accumulation caused by PDE4D ablation affects downstream effectors:

    • PDE4D-knockout cells show increased but delayed maximal CREB phosphorylation

    • PDE4D-knockout cells exhibit delayed return to basal levels compared with wild-type controls

    • PDE4A ablation has modest effects on CREB phosphorylation

    • PDE4B inactivation has no effect on CREB phosphorylation

This evidence demonstrates that PDE4D phosphorylation creates a specific regulatory mechanism for β-adrenergic signaling that cannot be compensated by other PDE4 subtypes, highlighting the non-redundant functions of these closely related enzymes .

How does targeted inhibition of phosphorylated PDE4B affect cognitive function and anxiety-related behaviors?

Research using PDE4B-specific inhibition models demonstrates significant effects on cognitive function and anxiety:

• Molecular and Cellular Effects:

  • A catalytic domain mutant form of PDE4B (Y358C) with decreased ability to hydrolyze cAMP shows:

    • Facilitated phosphorylation of CREB

    • Decreased binding to DISC1 (Disrupted in Schizophrenia 1)

    • Upregulation of DISC1 and β-Arrestin in hippocampus and amygdala

• Behavioral Outcomes:

  • PDE4B Y358C mice display:

    • Decreased anxiety

    • Increased exploration

    • Cognitive enhancement across several tests of learning and memory

• Synaptic and Neurogenic Changes:

  • Enhanced long-term potentiation

  • Impaired depotentiation ex vivo

  • Enhanced neurogenesis

• Contextual Fear Memory Effects:

  • Contextual fear memory is intact at 24h but decreased at 7 days in PDE4B Y358C mice

  • This effect can be replicated pharmacologically with non-selective PDE4 inhibitors

  • Suggests cAMP signaling by PDE4B is involved in a very late phase of consolidation

These findings establish specific inhibition of PDE4B as a promising therapeutic approach for disorders of cognition and anxiety, and a putative target for treating pathological fear memory .

What is the expression profile of PDE4 subtypes in lymphocytes from asthmatic individuals, and how does this inform therapeutic targeting?

Studies examining PDE4 subtype expression in asthma provide important insights for therapeutic targeting:

• Expression Profile in Lymphocytes:

  • In both CD4+ and CD8+ lymphocytes from healthy and mild asymptomatic asthmatic subjects:

    • PDE4A, PDE4B, and PDE4D are all detected

    • No significant differences in expression are observed between healthy and asthmatic groups

    • In CD8+ lymphocytes, enzyme subtype expression is lower and shows more intersubject variability

• Previous Findings on PDE4 in Atopic Conditions:

  • Earlier studies reported:

    • PDE4A and PDE4B2 present in both CD4+ and CD8+ cells

    • PDE4D expressed only in CD8+ cells

    • Increased PDE4A and PDE4B2 expression in CD4+ cells from atopic subjects, although this did not result in significantly higher cAMP PDE activity

• Implications for Therapeutic Targeting:

  • Understanding the PDE4 subtype distribution in inflammatory cells is crucial for developing targeted therapies

  • The presence of all three subtypes in lymphocytes suggests potential functional redundancy, which may affect the efficacy of subtype-specific inhibitors

  • The intersubject variability in expression, particularly in CD8+ cells, suggests potential for personalized approaches to PDE4 inhibition

This expression profile data provides important context for developing therapeutic strategies targeting specific PDE4 subtypes in asthma and other inflammatory conditions .

What are the recommended storage conditions and stability considerations for Phospho-PDE4B/PDE4C/PDE4D antibodies?

Proper storage is crucial for maintaining antibody performance over time:

Important stability considerations:

• Buffer Composition: The antibody is typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability

• Freeze-Thaw Cycles: Avoid repeated freeze-thaw cycles as this can lead to denaturation and decreased antibody performance

• Aliquoting Strategy: For antibodies requiring frequent use, consider creating small aliquots before freezing to minimize freeze-thaw cycles

• Working Dilutions: Diluted working solutions should be prepared fresh for each experiment rather than stored for extended periods

Following these storage guidelines will help ensure optimal antibody performance and reproducible research results .

What are the most effective strategies for troubleshooting non-specific signals when using Phospho-PDE4B/PDE4C/PDE4D antibodies?

When encountering non-specific signals with Phospho-PDE4B/PDE4C/PDE4D antibodies, implement these troubleshooting strategies:

• Optimization of Blocking Conditions:

  • Increase blocking time or concentration (typically using 5% BSA or milk)

  • Consider alternative blocking agents if background persists

  • For phospho-specific antibodies, use phospho-blocker solutions when available

• Antibody Dilution Optimization:

  • Test a range of dilutions beyond the recommended 1:500-1:2000 for Western blot

  • Titrate antibody concentration systematically to find optimal signal-to-noise ratio

• Sample Preparation Refinement:

  • Ensure complete lysis and proper protein denaturation

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Consider additional purification steps for complex samples

• Controls to Identify Non-Specific Binding:

  • Include phosphatase-treated samples as negative controls

  • Use lysates from cells with phospho-defective mutations (e.g., S190A)

  • Consider using PDE4-deficient cells as specificity controls

• Signal Enhancement Strategies:

  • For weak specific signals, consider using amplification systems compatible with phospho-epitopes

  • Optimize exposure times for Western blot detection

  • For IHC applications, test various antigen retrieval methods

These methodical troubleshooting approaches can help distinguish specific phospho-PDE4 signals from non-specific background, improving experimental reliability and data interpretation .